Influence of Enteral Microbiome on Mortality of Patients With Cardiogenic Shock
NCT ID: NCT06006754
Last Updated: 2025-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
40 participants
OBSERVATIONAL
2023-08-30
2025-02-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study aims to provide a deeper understanding of the role of the enteral microbiome and microbiome dependent metabolites in mortality and disease progression of patients with cardiogenic shock.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Clinical, Laboratory and Microbiological Predictors of Treatment Outcomes in Infective Endocaridtis
NCT02466139
Acute Intestinal Failure in Critically Ill Patients and Microbial Translocation
NCT03861325
Gut Microbiota in Patients With Peripheral Arterial Disease and Chronic Limb-threatening Ischemia
NCT05757297
Cutaneous Microbiota Evolution in ICU Patients With CVC (ICMc)
NCT06095076
From Commensalism to Pathogenicity: Exploring the Pathophysiology of Bacteremia to Better Understand Enterococcus Faecalis Infective Endocarditis
NCT07313865
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cardiogenic shock
Observational study
No intervention: observational study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Observational study
No intervention: observational study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* signs of cardiogenic shock regardless of etiology
* lactate \>3mmol/L
* and signs of organ dysfunction (urine output \<30 ml/h, cold extremities, altered mental status)
* and systolic blood pressure \<90 mmHg for \>30 minutes or need for vasopressor therapy
Exclusion Criteria
* antibiotic treatment within \>24h
* chronic inflammatory bowel disease
* short bowel syndrome
* artificial bowel outlet
* persistent diarrhea or vomiting in the past 3 months
* simultaneous participation in another interfering nutrition study
* active chemo or radiation therapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Essen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chistos Rammos
Professor Dr. med.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christos Rammos, Prof. Dr.
Role: STUDY_CHAIR
University Clinic Essen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Essen
Essen, North Rhine-Westphalia, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Microbiome-Shock-Trial
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.